Cyclacel Pharmaceuticals, Inc. (CYCC) - Dilution Analysis

10-Q filing | 5.5M shares outstanding

10-K filing | 5.5M shares outstanding

POS AM filing: This is a post-effective amendment to correct an incorrect hyperlink in the exhibit table of the initial registration statement, with no additional securities being registered.

8-K filing: Cyclacel Pharmaceuticals, Inc. amended and restated series A, B, and C common stock purchase warrants to remove the Ownership Limitation.

10-Q filing | 2.2M shares outstanding

S-1 filing: This prospectus relates to the offer and resale from time to time by the selling shareholders identified in this prospectus of up to (i) 654,000 shares of Common Stock underlying shares of Series F preferred stock held by certain accredited investors; (ii) 1,962,000 shares of Common Stock pursuant to the series A common stock purchase warrant, series B common stock purchase warrant and series C common stock purchase warrant issued to the Investors; (iii) 1,643 shares of Common Stock held by Helena Global Investment Opportunities 1 Ltd.; (iv) 145,833 shares of Common Stock held by the Company's chief executive officer, Datuk Dr. Doris Wong Sing Ee; and (v) 58,476 shares of Common Stock held by the Company's former chief executive officer, David Lazar.

8-K filing: Stock split 1-for-15 | Outstanding: 356,357,531 → 23,757,168

10-Q filing | 356.4M shares outstanding

8-K filing: Stock split 1-for-16 | Outstanding: 246,357,569 → 15,397,348

S-1 filing: This S-1 filing relates to the offer and resale from time to time by the selling shareholders of up to 170,026,676 shares of common stock.

10-K filing | 207.3M shares outstanding

8-K filing: David E. Lazar sold Series C and Series D Convertible Preferred Stock to Datuk Dr. Doris Wong Sing Ee, resulting in the Investor holding approximately seventy percent (70%) of the issued and outstanding shares of the Company on an as-converted basis, and the investor converted the Series C and Series D shares into common stock. ($6.3M proceeds)

8-K filing: Cyclacel Pharmaceuticals, Inc. amended its certificate of incorporation to increase the number of authorized shares of common stock and removed ownership limitations on Series C and Series D Convertible Preferred Stock, subsequently issuing 2,100,000 shares of Series D Convertible Preferred Stock to David Lazar.

8-K filing: Cyclacel Pharmaceuticals' stockholders approved a reverse stock split at a ratio not less than 1:4 and not more than 1:16, and Mr. Lazar paid $2,100,000 to the Company on February 6, 2025, for 2,100,000 shares of Series D Preferred Stock. ($2.1M proceeds)

8-K filing: Cyclacel Pharmaceuticals, Inc. closed an offering on November 14, 2024, involving the exercise of Series B Warrants for 4,968,945 shares of common stock at $0.415 per share, resulting in gross proceeds of approximately $2.1 million before deducting fees and expenses. ($2.1M proceeds)

10-Q filing | 1.1M shares outstanding

S-1 filing: This S-1 filing outlines a proposed offering of common stock, common stock warrants, and pre-funded warrants by Cyclacel Pharmaceuticals, Inc. for general corporate purposes and working capital.

10-Q filing | 1.1M shares outstanding

10-Q filing | 1.3M shares outstanding

S-1 filing: This S-1 filing details an offering of common stock by selling stockholders.

8-K filing: Cyclacel Pharmaceuticals, Inc. entered into a securities purchase agreement for a private placement involving the issuance and sale of common stock, pre-funded warrants, and common warrants, which closed on May 2, 2024, with gross proceeds of approximately $8.0 million. ($0.0M proceeds)

RW filing: The Company has determined not to pursue the public offering to which the Registration Statement relates and requests withdrawal of the Registration Statement.

S-1/A filing: This S-1/A filing relates to an offering of common stock, warrants, and pre-funded warrants by Cyclacel Pharmaceuticals, Inc.

S-1/A filing: This is an S-1/A filing for Cyclacel Pharmaceuticals, Inc. detailing the offering of 5,952,380 shares of common stock, common stock warrants to purchase up to 11,904,760 shares, and pre-funded warrants to certain purchasers.

S-1 filing: Cyclacel Pharmaceuticals, Inc. is filing an S-1 registration statement for an offering of common stock, common stock warrants, and pre-funded warrants.

10-K filing | 0.6M shares outstanding

S-1/A filing: This prospectus relates to the proposed resale from time to time, by the selling security holders identified in this prospectus of up to 411,969 shares of Cyclacel Pharmaceuticals, Inc. common stock, $0.001 par value per share, which are issuable upon the exercise of certain outstanding warrants.

S-1 filing: This S-1 filing relates to the offering of common stock and warrants, including shares issuable upon exercise of warrants previously issued under the Securities Purchase Agreement and Placement Agency Agreement.

8-K filing: Cyclacel Pharmaceuticals, Inc. entered into a securities purchase agreement with institutional investors for a registered direct offering of 168,500 shares and pre-funded warrants to purchase up to 219,700 shares, along with a concurrent private placement of unregistered warrants to purchase up to 388,200 shares, and a concurrent insider private placement of 7,956 shares to executive officers.

10-Q filing | 12.6M shares outstanding

S-3 filing: The company may offer and sell common stock, preferred stock, and debt securities from time to time in one or more offerings of up to $100,000,000 in aggregate offering price.

10-Q filing | 12.6M shares outstanding

10-Q filing | 12.5M shares outstanding

10-K filing | 12.5M shares outstanding

10-Q filing | 10.0M shares outstanding

10-Q filing | 11.4M shares outstanding

10-Q filing | 10.0M shares outstanding

10-K filing | 6.2M shares outstanding

10-Q filing | 6.2M shares outstanding

10-Q filing | 6.2M shares outstanding

10-Q filing | 9.2M shares outstanding

8-K filing: Cyclacel Pharmaceuticals, Inc. entered into an Underwriting Agreement to issue and sell 1,807,143 shares of common stock at a public offering price of $7.00 per share, expecting to receive approximately $12.65 million in net proceeds. ($12.65M proceeds)

10-K filing | 7.1M shares outstanding

8-K filing: Cyclacel Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with Acorn Bioventures, LP to sell Common Shares, Series B Convertible Preferred Stock, and Warrants for gross proceeds of approximately $7 million. ($21.0M proceeds)

10-Q filing | 4.9M shares outstanding

10-Q filing | 4.9M shares outstanding

10-Q filing | 4.9M shares outstanding

8-K filing: Cyclacel Pharmaceuticals, Inc. entered into a co-placement agency agreement and a securities purchase agreement for the purchase and sale of common stock, pre-funded warrants, and accompanying common stock warrants.

8-K filing: Stock split 1-for-20 | Outstanding: 17,199,974 → 859,998

S-1 filing: S-1 filing for offering of Common Stock and Pre-Funded Warrants to Purchase Shares of Common Stock.

10-K filing | 17.2M shares outstanding